# OnCo record kan-her2-mrd (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/kan-her2-mrd/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "kan-her2-mrd", "NCT05388149" ;
  schema:name "KAN-HER2 MRD"@en ;
  schema:alternateName "KAN-HER2"@en ;
  schema:description "A small Canadian trial adding neratinib to standard treatment for women with HER2-positive breast cancer whose blood test shows leftover cancer after surgery."@en ;
  schema:url <https://onco.cc/trials/kan-her2-mrd/> ;
  schema:dateModified "2026-11-04"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05388149> ;
  onco:status "recruiting" ;
  onco:phase "2" ;
  schema:startDate "2022-12-06" ;
  onco:cancers <https://onco.cc/cancers/breast-her2-positive/> ;
  onco:technologies <https://onco.cc/technologies/mrd-testing/> ;
  onco:targets <https://onco.cc/targets/her2/> ;
  onco:drugs <https://onco.cc/drugs/neratinib/>, <https://onco.cc/drugs/trastuzumab-emtansine/>, <https://onco.cc/drugs/radar-mrd/> ;
  onco:terms <https://onco.cc/terms/mrd/>, <https://onco.cc/terms/ctdna/>, <https://onco.cc/terms/tumour-informed-assay/> .